Antibody evolution immunogens
US-2015366961-A1 · Dec 24, 2015 · US
Immunogens of HIV-1 broadly neutralizing antibodies, methods of generation and uses thereof
US9707290B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9707290-B2 |
| Application number | US-201514642929-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 10, 2015 |
| Priority date | Sep 10, 2012 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application relates to immunogens of broadly neutralizing monoclonal antibodies specific for HIV-1, such as broad and potent neutralizing monoclonal antibodies specific for HIV-1 and their gernation and methods of use. Broad neutralization suggests that the antibodies can neutralize HIV-1 isolates from different individuals. Immunogens or vaccines which may elicit such antibody associated responses are useful in pharmaceutical compositions for the prevention and treatment of HIV, and for the diagnosis and monitoring of HIV infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A 10E8 immunogen having the amino acid sequence comprising (a) 10E8_T298v2 (SEQ ID NO: 231) GSEVSQNDIIKALASPLINDGMVVSDFADHVITREQNAPTGLPVEPVGVA IPHTDSKYVRQNAISVGILAEPVNFEDAGGEPDPVPVRVVFMLALGNWFD ITNVLWWI KA VIQDADFMQQLL R MNDDEIYQSIYTRISEAAGMAGIHFRR HYVRHL G or (b) 10E8_T93v2_RT1_1 (SEQ ID NO: 232) GEAQRVRQEAKERMKRAVEKFKKELKEFNTEVEKKEPRQQRIQKWEQIVE ERAKKAEDEVKKVGKEA A DRAAKLGQDPQVNWFDISQILWDV K KLIQEAI EEIRKALEQMRRWLQRG or (c) 10E8_T93v2RT12-1 (SEQ ID NO: 201) GKADEVREKARRRMEQAVEEFKRRLRQFEEKVKQKEPRDDEINRWIDIVK KKADEAKKRVEEVGDQAADEAAQLGNDPNVNWFDITNVLWDVKKLTEKAI NDIDDALKKMKDWLESG or (d) 10E8_T93v2RT12-2 (SEQ ID NO: 202) GKADEVREKARRRMEQAVEEFKRRLRQFEEKVKQKEPRDDEINRWIDIVK KKADEAKKRVEEVGDQAADEAAQLGNDPNVNWFSITKVLWDVKKLTEKAI NDIDDALKKMKDWLESG or (e) 10E8_T93v2RT12-3 (SEQ ID NO: 203) GKADEVREKARRRMEQAVEEFKRRLRQFEEKVKQKEPRDDEINRWIDIVK KKADEAKKRVEEVGDQAADEAAQLGNDPNVSWFNISNVLWDVRKLTEKAI NDIDDALKKMKDWLESG or (f) 10E8_T93v2RT12-4 (SEQ ID NO: 204) GKADEVREKARRRMEQAVEEFKRRLRQFEEKVKQKEPRDDEINRWIDIVK KKADEAKKRVEEVGDQAADEAAQLGNDPNVNWFDISRVLWDVKKLTEKAI NDIDDALKKMKDWLESG or (g) 10E8_T93v2RT12-5 (SEQ ID NO: 205) GKADEVREKARRRMEQAVEEFKRRLRQFEEKVKQKEPRDDEINRWIDIVK KKADEAKKRVEEVGDQAADEAAQLGNDPNVNWFDITQVLWDVKKLTEKAI NDIDDALKKMKDWLESG or (h) 10E8_T117v2-1 (SEQ ID NO: 233) NAMQGIHFRRHYVRHLPKEVSQNDIIKALASPLINDGMVVSDFADHVITR EQNFPTGLPVEPVGVAIPHTDSKYVRQNAISVGILAEPVNFEDAGGEPDP VPVRVVFMLALGNWFDITNVLWWIKAVIQDEDFMQQLLVMNDDEIYQSIY TRISE or (i) 10E8_T117v2-2 (SEQ ID NO: 207) NAMQGIHFRRHYVRHLPKEVSQNDIIKALASPLINDGMVVSDFADHVITR EQNFPTGLPVEPVGVAIPHTDSKYVRQNAISVGILAEPVNFEDAGGEPDP VPVRVVFMLALGNWFSITKVLWWIKAVIQDEDFMQQLLVMNDDEIYQSIY TRISE or (j) 10E8_1117v2-3 (SEQ ID NO: 208) NAMQGIHFRRHYVRHLPKEVSQNDIIKALASPLINDGMVVSDFADHVITR EQNFPTGLPVEPVGVAIPHTDSKYVRQNAISVGILAEPVNFEDAGGEPDP VPVRVVFMLALGSWFNISNVLWWIRAVIQDEDFMQQLLVMNDDEIYQSIY TRISE or (k) 10E8_T117v2-4 (SEQ ID NO: 209) NAMQGIHFRRHYVRHLPKEVSQNDIIKALASPLINDGMVVSDFADHVITR EQNFPTGLPVEPVGVAIPHTDSKYVRQNAISVGILAEPVNFEDAGGEPDP VPVRVVFMLALGNWFDISRVLWWIKAVIQDEDFMQQLLVMNDDEIYQSIY TRISE or (l) 10E8_T117v2-5 (SEQ ID NO: 210) NAMQGIHFRRHYVRHLPKEVSQNDIIKALASPLINDGMVVSDFADHVITR EQNFPTGLPVEPVGVAIPHTDSKYVRQNAISVGILAEPVNFEDAGGEPDP VPVRVVFMLALGNWFDITQVLWWIKAVIQDEDFMQQLLVMNDDEIYQSIY TRISE or (m) 10E8_T93v2RT12-1_P2 (SEQ ID NO: 234) GKADEVREKARRRMEQAVEEFKRRLRQFEEKVKQKEPRDDEINRWIDIVK KKADEAKKRVEEVGDQAADEAAQLGNDPNVNWFDITNVLWDVKKLTEKAI NDIDDALKKMKDWLESGGQYIKANSKFIGITEL or (n) 10E8_T93v2RT12-2_P2 (SEQ ID NO: 235) GKADEVREKARRRMEQAVEEFKRRLRQFEEKVKQKEPRDDEINRWIDIVK KKADEAKKRVEEVGDQAADEAAQLGNDPNVNWFSITKVLWDVKKLTEKAI NDIDDALKKMKDWLESGGQYIKANSKFIGITEL or
Assignees
Inventors
Classifications
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
- A61K39/21Primary
Retroviridae, e.g. equine infectious anemia virus · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
- A61K39/12Primary
Viral antigens · CPC title
characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9707290B2 cover?
- The present application relates to immunogens of broadly neutralizing monoclonal antibodies specific for HIV-1, such as broad and potent neutralizing monoclonal antibodies specific for HIV-1 and their gernation and methods of use. Broad neutralization suggests that the antibodies can neutralize HIV-1 isolates from different individuals. Immunogens or vaccines which may elicit such antibody asso…
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative, Scripps Research Inst
- What technology area does this patent fall under?
- Primary CPC classification A61K39/21. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).